Viridian Therapeutics (1S1) Stock Price & Analysis
1S1 Stock Chart & Stats
- Day’s Range
- EUR 21.80 - EUR 21.80
- 52-Week Range
- EUR 11.20 - EUR 28.58
- Previous Close
- EUR 21.40
- Volume
- N/A
- Average Volume (3M)
- 9
- Market Cap
- EUR 2.50B
- Enterprise Value
- EUR 1.34B
- Total Cash (Recent Filing)
- EUR 981.53M
- Total Debt (Recent Filing)
- EUR 242.88M
- Price to Earnings (P/E)
- ―
- Beta
- -0.03
- Next Earnings
- Nov 04, 2026 (Est.)
- EPS Estimate
- -0.91
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth
The step-up to approximately $71M of TTM revenue demonstrates meaningful progress from Viridian’s historically small revenue base. Sustained revenue expansion could improve development funding capacity and validate commercial or partnership interest as the pipeline advances.
Balance Sheet Flexibility
Substantial equity and relatively low leverage provide Viridian with more financial flexibility than a highly indebted development-stage biotech. This supports continued investment in clinical programs and gives management greater capacity to manage financing needs over the next several quarters.
Funding And Manufacturing Readiness
The capital raise and full repayment of the Hercules loan strengthen near-term funding flexibility by reducing financing obligations. The WuXi manufacturing agreement also supports execution and potential commercialization readiness as Viridian progresses its development programs.
Bears Say
Persistent Operating Losses
The very large net loss and deeply negative margins show that Viridian’s current operations are not yet economically self-sustaining. Continued heavy operating expenses could delay breakeven and require additional funding before the pipeline can produce durable product revenue.
Severe Cash Burn
Operating and free cash flow remain substantially negative, indicating that Viridian consumes significant cash while advancing its programs. Persistent burn increases dependence on external financing and can constrain development pace or shareholder economics if losses continue.
No Approved Commercial Product
Without an approved product generating recurring sales, Viridian’s future revenue depends on successful clinical development, regulatory approval, and commercialization. Until those milestones are achieved, ongoing operations remain dependent on access to external capital.
1S1 FAQ
What was Viridian Therapeutics’s price range in the past 12 months?
What is Viridian Therapeutics’s market cap?
When is Viridian Therapeutics’s upcoming earnings report date?
How were Viridian Therapeutics’s earnings last quarter?
Is Viridian Therapeutics overvalued?
Does Viridian Therapeutics pay dividends?
What is Viridian Therapeutics’s EPS estimate?
How many shares outstanding does Viridian Therapeutics have?
What happened to Viridian Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Viridian Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Viridian Therapeutics Stock Smart Score
Company Description
Viridian Therapeutics
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Stephen F. Mahoney
- Employees
- 252
- Website
- www.viridiantherapeutics.com
- Address
- 221 Crescent Street, Waltham, MA, 02453, US
Viridian Therapeutics (1S1) Earnings & Revenues
1S1 Earnings Call
Earnings Call SentimentPositive
The earnings call reflects significant progress and positive developments in the company's pipeline, particularly with the completion of enrollment in the THRIVE trial, a strong financial position, and positive regulatory interactions. However, there are challenges, such as the extended timeline for BLA submission and concerns about hearing impairment assessments in clinical trials.
View all DE:1S1 earnings summaries1S1 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 1 | 5 |
| Technical Analysis | 3 | 1 | 5 |
| Moving Averages | 12 | 0 | 0 |
